Aarti Pharmalabs Corrects Dividend Financial Year to FY26
Aarti Pharmalabs Limited corrected its dividend record date announcement. The dividend declared is for Financial Year 2025-26, correcting a prior mention of FY 2024-25. This clarification was issued on February 10, 2026.
The impact is low as it is a minor correction of a financial year mentioned in a previous announcement and does not change the substance of the dividend declaration.
The announcement is a correction of a typographical error and does not introduce new material financial information or significantly alter the existing understanding of the dividend declaration.
Aarti Pharmalabs Limited has issued a corrigendum to its earlier intimation regarding the record date for dividend. The company has clarified a typographical error in the previously announced date, specifying that the dividend declared pertains to the Financial Year 2025-26, not Financial Year 2024-25 as stated before.
This correction was communicated on February 10, 2026, referencing the original intimation dated February 09, 2026. The company confirmed that all other details in the previous intimation remain unchanged.
What to do with a filing like this
Aarti Pharmalabs Limited filed this with the NSE as a statutory disclosure, categorised under dividend. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarti Pharmalabs Limited. Read the original for the full detail.